Pao-Ju Tseng
Primary Care · Flushing, NYNPI 1386163012
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 40.9% of the total. Reporting peaked in 2022 at $2,322 and has fallen 75.3% since, to $574 in 2025. Among primary care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $34.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Gilead$1K
- Novo Nordisk$394
- Amgen$262
- Pfizer$258
- Phathom Pharmaceuticals, Inc.$177
- plus $2K from 17 others
What the payments were for
- Food & beverage$6,315100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 72 | $2,585 |
| Gilead | 34 | $1,022 |
| Novo Nordisk | 12 | $394 |
| Amgen | 9 | $262 |
| Pfizer | 4 | $258 |
| Phathom Pharmaceuticals, Inc. | 5 | $177 |
| Novartis | 2 | $163 |
| Madrigal Pharmaceuticals | 1 | $150 |
| Esperion Therapeutics, Inc. | 1 | $150 |
| Sanofi | 1 | $147 |
| Lilly USA, LLC | 7 | $135 |
| GSK | 6 | $133 |
| IBSA Pharma Inc. | 1 | $125 |
| Nestle Healthcare Nutrition Inc. | 6 | $112 |
| Merck | 4 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $79 |
| Boehringer Ingelheim | 4 | $78 |
| Amarin Pharma, Inc. | 4 | $77 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $58 |
| Sun Pharmaceutical Industries Inc. | 1 | $48 |
| Dermavant Sciences, Inc. | 1 | $42 |
| Phadia US Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,321 in reported general payments places this provider in the 95th percentile of 239 primary care providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 429 | $189,698 |
| JardianceEmpagliflozin | 92 | $83,068 |
| RestasisCyclosporine | 100 | $64,893 |
| VemlidyTenofovir Alafenamide | 37 | $51,838 |
| RybelsusSemaglutide | 25 | $39,033 |
| ProliaDenosumab | 22 | $37,822 |
| CreonLipase/Protease/Amylase | 22 | $37,421 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $30,011 |
| OzempicSemaglutide | 23 | $26,464 |
| JanuviaSitagliptin Phosphate | 38 | $26,109 |
| JentaduetoLinagliptin/Metformin Hcl | 37 | $22,111 |
| Diclofenac Epolamine | 62 | $21,930 |
| LinzessLinaclotide | 20 | $13,739 |
| Diclofenac Sodium | 35 | $11,853 |
| EliquisApixaban | 15 | $10,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Creon, Linzess | $2,585 | $116,053142 claims |
| Boehringer IngelheimJardiance, Jentadueto | $78 | $105,179129 claims |
| Novo NordiskRybelsus, Ozempic | $394 | $65,49748 claims |
| MerckJanumet, Januvia | $85 | $56,12170 claims |
| GileadVemlidy | $1,022 | $51,83837 claims |
| AmgenProlia | $262 | $37,82222 claims |
| PfizerEliquis | $258 | $10,04315 claims |
| GSKShingrix | $133 | $2,87715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 primary care providers in New York.
Other primary care in Flushing
- Vanessa WangFlushing$10K
- Jian Xin BertolinoFlushing$3K
- Xue GaoFlushing$3K
- Jiyoung YangFlushing$2K
- Dorothy KleinertNew York$27K
- Stephanie KhanForest Hills$16K
- Albert MarcanoJackson Heights$15K
- Elizabeth GattmanJamestown$10K
- Elizabeth SmithWaterloo$9K
- Eric RodriguezSyracuse$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.